ClinicalTrials.gg
CompletedNCT04421885Updated Aug 12, 2020

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

A Phase 1 interventional study of Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference and Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test in Healthy Volunteers, sponsored by Spero Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-12.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A bioequivalence and food-effect study comparing two tablet formulations of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, adult, male or female, 18 to 55 years of age
  • Continuous non-smoker.
  • (BMI) ≥ 18.0 and ≤ 32.0 kg/m2.
  • Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or ECGs.
  • Has suitable venous access for repeated blood sampling.
  • A female of must agree to abstain from sexual activity that could lead to pregnancy.
  • A female of non-childbearing potential.
  • Understands the study procedures in the form (ICF), and be willing and able to comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected to have during the conduct of the study.
  • History or presence of medical or psychiatric condition or disease.
  • History of any illness that might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  • History of significant allergic disease requiring treatment.
  • History or presence of alcoholism or drug abuse.
  • History or presence of or idiosyncratic reaction to the study drug or related compounds.
  • History of known genetic metabolism anomaly associated with carnitine deficiency.
  • Female subjects with a positive pregnancy test or who are lactating.
  • Positive urine drug or alcohol results.
  • Positive results for (HIV 1 and 2), surface antigen (HBsAg), or virus (HCV).
  • interval is > 460 msec (males) or > 470 msec (females) or has findings deemed abnormal with clinical significance by the PI or designee at the screening visit.
  • Estimated \< 80 mL/min at the screening visit.
  • Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    A: TBPM-PI-HBr (Reference - fasted)

    600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.

    Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference

  • Experimental
    B: TBPM-PI-HBr (Test - fasted)

    600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions.

    Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test

  • Experimental
    C: TBPM-PI-HBr (Test - fed)

    600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions.

    Drug: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve extrapolated to infinity (AUC0-∞).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  2. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  3. Maximum plasma concentration (Cmax).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

Secondary outcomes

  1. Time to the maximum plasma concentration (Tmax).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  2. Terminal elimination half-life (t½).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  3. Apparent total body clearance (CL/F)

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  4. Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).

    Time frame: 24h (Day 2) post dose (Arms: A, B, C)

  5. Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug.

    ECG, Clinical Laboratories, Vitals Signs and Physical Exams will be used as a safety measure to detect any AEs.

    Time frame: 12 to 14 days after the last dose of study drug

  6. Area under the curve extrapolated to infinity (AUC0-∞).

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

    Time frame: 24h (Day 2) post dose (Arms: B, C)

  7. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t).

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

    Time frame: 24h (Day 2) post dose (Arms: B, C)

  8. Maximum plasma concentration (Cmax).

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

    Time frame: 24h (Day 2) post dose (Arms: B, C)

  9. Time to the maximum plasma concentration (Tmax).

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

    Time frame: 24h (Day 2) post dose (Arms: B, C)

  10. Terminal elimination half-life (t½).

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

    Time frame: 24h (Day 2) post dose (Arms: B, C)

  11. Apparent total body clearance (CL/F)

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

    Time frame: 24h (Day 2) post dose (Arms: B, C)

  12. Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).

    TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions.

    Time frame: 24h (Day 2) post dose (Arms: B, C)

07

Study locations

1 site
  • Medical Facility
    Tempe, Arizona 85283, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Jul 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 9, 2020
StartActual
Jun 1, 2020
Primary completionActual
Jul 11, 2020
CompletionActual
Jul 29, 2020
Last update
Aug 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04421885
Lead sponsor
Spero Therapeutics
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Jun 1, 2020
Primary completion
Jul 11, 2020
Completion
Jul 29, 2020
Last update
Aug 12, 2020

Study contacts

David Melnick
study director · Spero Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebipenem

Start the discussion